FDA approves Promacta sNDA

FDA approved an sNDA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for once-daily use of Promacta eltrombopag in patients with severe aplastic anemia ( SAA) who have had an insufficient response to immunosuppressive therapy.

FDA granted Promacta breakthrough therapy designation for the rare disorder in which the bone marrow fails to make enough new blood cells. ...